NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
Clinical Trials
69 trialsNCT03798626 2026-01-27
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
Phase 1 Completed
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04631744 2025-12-18
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Weill Medical College of Cornell University
Phase 2 Completed
NCT05052723 2025-11-19
Cabozantinib and Pembrolizumab in Metastatic Pancreas
University of Kentucky
Phase 2 Completed
NCT04477512 2025-11-12
Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Washington University School of Medicine
Phase 1 Completed
NCT01935934 2025-10-01
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03685448 2025-08-08
UNICAB
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Completed
NCT03967522 2025-08-08
CABRAMET
Centre Leon Berard
Phase 2 Completed
NCT01979393 2025-08-01
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT01441947 2025-05-25
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT04804813 2025-04-11
Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma
Takeda
Completed
NCT04338269 2025-04-04
CONTACT-03
Hoffmann-La Roche
Phase 3 Completed
NCT04316182 2025-03-30
ACTION
Fundacion Clinic per a la Recerca Biomédica
Phase 2 Completed
NCT03149822 2025-03-13
Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma
University of Colorado, Denver
Phase 1/2 Completed
NCT04511455 2025-01-30
Cabozantinib for Patients with Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT04522908 2025-01-30
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Completed
NCT04767906 2025-01-23
CaPture
University of Leipzig
Phase 2 Completed
NCT02761057 2025-01-13
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Phase 2 Completed
NCT05007613 2025-01-01
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
Phase 2 Completed
NCT03425201 2024-12-31
NICARAGUA
Fundacion CRIS de Investigación para Vencer el Cáncer
Phase 1/2 Completed
NCT03370718 2024-12-10
Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03534804 2024-11-26
PemCab
University of Utah
Phase 2 Completed
NCT03299946 2024-09-03
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT05265988 2024-07-31
MERIDIAN
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Phase 2 Completed
NCT03667482 2024-07-23
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03200587 2024-07-03
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
University of Utah
Phase 1 Completed
NCT00940225 2024-04-25
Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Exelixis
Phase 2 Completed
NCT01466036 2024-03-05
Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02592356 2024-03-05
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
Phase NA Completed
NCT04540705 2024-02-28
PIVOT IO 011
Bristol-Myers Squibb
Phase 1 Completed
NCT04134390 2024-01-09
CABOMAYOR
Spanish Oncology Genito-Urinary Group
Phase 2 Completed
NCT01755195 2024-01-03
Cabozantinib for Adults With Advanced Soft Tissue Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01709435 2023-12-22
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT02795156 2023-12-05
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
Phase 2 Completed
NCT03468985 2023-10-17
Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02101736 2023-05-24
NF105-CABO
University of Alabama at Birmingham
Phase 2 Completed
NCT03428217 2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2 Completed
NCT04661852 2023-02-15
Cabozantinib With Topotecan-Cyclophosphamide
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04205799 2023-02-13
CABOCOL-01
Centre Francois Baclesse
Phase 2 Completed
NCT01822522 2023-01-10
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
National Cancer Institute (NCI)
Phase 1 Completed
NCT04510688 2022-10-26
SRWEC
Spanish Oncology Genito-Urinary Group
Completed
NCT02071862 2022-07-20
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Calithera Biosciences, Inc
Phase 1 Completed
NCT03542877 2022-07-15
Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer
University of Colorado, Denver
Phase 2 Completed
NCT01630590 2022-03-25
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01574937 2021-08-06
XL-184+Abiraterone in Post-Chemo CRPC
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01812668 2021-08-05
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT02216578 2021-07-15
Ph II CABOGIST in GIST
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT02260531 2021-05-20
Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed